Innoviva Total Liabilities and Share Holders Equity 2010-2024 | INVA
Innoviva total liabilities and share holders equity from 2010 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Innoviva Annual Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2023 |
$1,244 |
| 2022 |
$1,231 |
| 2021 |
$926 |
| 2020 |
$1,000 |
| 2019 |
$725 |
| 2018 |
$548 |
| 2017 |
$367 |
| 2016 |
$379 |
| 2015 |
$409 |
| 2014 |
$522 |
| 2013 |
$681 |
| 2012 |
$369 |
| 2011 |
$259 |
| 2010 |
$331 |
| 2009 |
$181 |
Innoviva Quarterly Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2024-09-30 |
$1,232 |
| 2024-06-30 |
$1,225 |
| 2024-03-31 |
$1,268 |
| 2023-12-31 |
$1,244 |
| 2023-09-30 |
$1,188 |
| 2023-06-30 |
$1,118 |
| 2023-03-31 |
$1,130 |
| 2022-12-31 |
$1,231 |
| 2022-09-30 |
$1,328 |
| 2022-06-30 |
$1,138 |
| 2022-03-31 |
$1,107 |
| 2021-12-31 |
$926 |
| 2021-09-30 |
$887 |
| 2021-06-30 |
$789 |
| 2021-03-31 |
$1,088 |
| 2020-12-31 |
$1,000 |
| 2020-09-30 |
$922 |
| 2020-06-30 |
$880 |
| 2020-03-31 |
$788 |
| 2019-12-31 |
$725 |
| 2019-09-30 |
$676 |
| 2019-06-30 |
$642 |
| 2019-03-31 |
$590 |
| 2018-12-31 |
$548 |
| 2018-09-30 |
$278 |
| 2018-06-30 |
$339 |
| 2018-03-31 |
$277 |
| 2017-12-31 |
$367 |
| 2017-09-30 |
$391 |
| 2017-06-30 |
$372 |
| 2017-03-31 |
$392 |
| 2016-12-31 |
$379 |
| 2016-09-30 |
$371 |
| 2016-06-30 |
$378 |
| 2016-03-31 |
$388 |
| 2015-12-31 |
$409 |
| 2015-09-30 |
$438 |
| 2015-06-30 |
$462 |
| 2015-03-31 |
$489 |
| 2014-12-31 |
$522 |
| 2014-09-30 |
$554 |
| 2014-06-30 |
$606 |
| 2014-03-31 |
$605 |
| 2013-12-31 |
$681 |
| 2013-09-30 |
$666 |
| 2013-06-30 |
$595 |
| 2013-03-31 |
$592 |
| 2012-12-31 |
$369 |
| 2012-09-30 |
$384 |
| 2012-06-30 |
$399 |
| 2012-03-31 |
$218 |
| 2011-12-31 |
$259 |
| 2011-09-30 |
$283 |
| 2011-06-30 |
$303 |
| 2011-03-31 |
$315 |
| 2010-12-31 |
$331 |
| 2010-09-30 |
$213 |
| 2010-06-30 |
$232 |
| 2010-03-31 |
$250 |
| 2009-12-31 |
$181 |
| 2009-09-30 |
$183 |
| 2009-06-30 |
$206 |
| 2009-03-31 |
$215 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.195B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
